Skip to results
1-3 of 3
Authors: Paul R. Yarnold
Sort by
Journal Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions Free
Charles L. Bennett and others
The Oncologist, Volume 26, Issue 8, August 2021, Pages e1418–e1426, https://doi.org/10.1002/onco.13713
Published: 12 March 2021
Journal Article
Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada Free
Brian Chen and others
The Oncologist, Volume 24, Issue 4, April 2019, Pages 537–548, https://doi.org/10.1634/theoncologist.2018-0341
Published: 06 March 2019
Journal Article
Cancer-Associated Neutropenic Fever: Clinical Outcome and Economic Costs of Emergency Department Care Free
D. Mark Courtney and others
The Oncologist, Volume 12, Issue 8, August 2007, Pages 1019–1026, https://doi.org/10.1634/theoncologist.12-8-1019
Published: 01 August 2007
Advertisement
Advertisement